Latency and interval therapy affect the evolution in metastatic colorectal cancer

Nikbakht, Hamid; Jessa, Selin; Sukhai, Mahadeo A.; Arseneault, Madeleine; Zhang, Tong; Létourneau, Louis; Thomas, Mariam; Bourgey, Mathieu; Roehrl, Michael H. A.; Eveleigh, Robert; Chen, Eric X.; Krzyzanowska, Monika K.; Moore, Malcolm J.; Giesler, Amanda; Yu, Celeste; Bedard, Philippe L.; Kamel‐Reid, Suzanne; Majewski, Jacek; Siu, Lillian L.; Riazalhosseini, Yasser; Graham, Donna M.

doi:10.1038/s41598-020-57476-y

Cited by 8 publications

(7 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of secondary CRC amongst patients caused by first cancer radiotherapy treatment is an area of debate in clinical radiation oncology. The biggest challenge in evaluating the second CRC risk is the latency period of onset following initial radiotherapy treatment [46][47][48] . This recurrence is expected to occur many years after the first diagnosis 49 .…”

Section: Resultsmentioning

confidence: 99%

Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia

Abolaban

Djouider

2021

Preprint

View full text Add to dashboard Cite

Radiation-induced second cancer is one of the crucial late side effects of radiotherapy treatment of first cancer. Although the second cancer induction mechanism is not well understood yet, many factors are related to its occurrences, such as age at exposure, dose to the organ and surrounding tissues, treatment modalities, and family history of cancer. This study aims to provide long-term estimates of second cancer incidence amongst colon cancer survivors in Saudi Arabia. The lifetime attributable risk (LAR) after radiation treatment of the colon cancer was determined, between the age at exposure and up to 95 years, in a single-institution cohort of male and female cancer survivors whose age at treatment was in the range 43 to 85 years. Risk estimates varied significantly with age at exposure, gender, and organ dose.

show abstract

Section: Resultsmentioning

confidence: 99%

Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia

Abolaban

Djouider

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, sequencing of the tumor incurs additional expenses, and more importantly, may cause reporting delay and hinder timely initiation of ACT, negatively impacting survival [ 41 ]. Furthermore, tumor sequencing might not detect all relevant mutations because of intratumor heterogeneity [ 42 ] and may not capture subsequently emerging mutations as a result of treatment [ 43 ]. Another relevant shortcoming of the tumor-informed assays is that sequencing errors might be indistinguishable from actual mutations, especially if the mutations have a low VAF (<0.01%).…”

Section: Methodological Considerations For the Use Of Ctdna In Colmentioning

confidence: 99%

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review

Chakrabarti

Xie

Urrutia

et al. 2020

Cancers

View full text Add to dashboard Cite

The current standard treatment for patients with early-stage colon cancer consists of surgical resection, followed by adjuvant therapy in a select group of patients deemed at risk of cancer recurrence. The decision to administer adjuvant therapy, intended to eradicate the clinically inapparent minimal residual disease (MRD) to achieve a cure, is guided by clinicopathologic characteristics of the tumor. However, the risk stratification based on clinicopathologic characteristics is imprecise and results in under or overtreatment in a substantial number of patients. Emerging research indicates that the circulating tumor DNA (ctDNA), a fraction of cell-free DNA (cfDNA) in the bloodstream that originates from the neoplastic cells and carry tumor-specific genomic alterations, is a promising surrogate marker of MRD. Several recent studies suggest that ctDNA-guided risk stratification for adjuvant therapy outperforms existing clinicopathologic prognostic indicators. Preliminary data also indicate that, aside from being a prognostic indicator, ctDNA can inform on the efficacy of adjuvant therapy, which is the underlying scientific rationale for several ongoing clinical trials evaluating ctDNA-guided therapy escalation or de-escalation. Furthermore, serial monitoring of ctDNA after completion of definitive therapy can potentially detect cancer recurrence much earlier than conventional surveillance methods that may provide a critical window of opportunity for additional curative-intent therapeutic interventions. This article presents a critical overview of published studies that evaluated the clinical utility of ctDNA in the management of patients with early-stage colon cancer, and the potential of ctDNA to transform the adjuvant therapy strategies.

show abstract

“…Of interest are considerations about clonal selection pressure, specifically if the oligometastatic state has been reached by previous systemic chemotherapy or mixed responses [4]. In such cases originating from unfavourable clonal selection, ablation or resection, overcoming chemotherapy refractoriness in non- or mixed responders, may yield a significant benefit [30].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours

2020

View full text Add to dashboard Cite

Background: Clinical trials have proven a survival benefit from applying local therapies for oligometastatic cancers of various origin. Summary: Today, the definition of oligometastatic disease is based on limited lesion numbers and organ systems involved. Treatment guidelines by the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO) and several other groups suggest a threshold of up to 5 tumours. Established biological markers indicating the aggressiveness of a given tumour (and therefore suggesting local treatment only or the addition of or complete switch to systemic therapies) are missing, except for disease-free survival, the only recommended parameter for patient selection beyond lesion count. Key Message: The following article discusses clinical implications as well as local techniques established for the treatment of oligometastatic disease.

show abstract

Latency and interval therapy affect the evolution in metastatic colorectal cancer

Abstract: mutations in six clinically-relevant genes (APC, TP53, KRAS, NRAS, PIK3CA and BRAF) to the mutational burden of CRC by measuring variant allele frequencies using targeted ultra-deep sequencing.

Cited by 8 publications

References 61 publications

Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia

Lifetime Attributable Risk Estimates of Secondary Cancer after External Radiotherapy among Colorectal Cancer Survivors in Saudi Arabia

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review

Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours

Contact Info

Product

Resources

About